InvestSMART

Algorae Pharmaceuticals Limited (ASX:1AI)

ALERT: Price-sensitive ASX Announcement for 1AI
Current share price for 1AI : $0.008 -0.004 (-33.33%)+
Announcement
Release
31 Jul 2026 9:14AM
Price at Release
$0.012
Full Release
download
Summary
In the June 2026 Quarterly Activities Report, Algorae Pharmaceuticals Limited reported progress on its dual strategy in commercial pharmaceutical operations and AI drug-discovery. Key developments included partnerships expanding their commercial platform, advancements in AI drug-discovery with AlgoraeOS v2, and successful TGA engagements. Financially, the company maintained strong liquidity with $3.94 million in cash and undrawn financing facilities, positioning it well for future operations. Significant post-quarter achievements included securing a supply contract with NSW Health and receiving a grant to support further research validation.
Key Points
  • Algorae Pharmaceuticals Limited expanded its commercial platform to five agreements by partnering with Zydus Lifesciences Ltd and Torrent Pharmaceuticals Limited.
  • The Therapeutic Goods Administration (TGA) accepted the Stage 1 registration dossiers for two AlgoraeRx products.
  • AlgoraeOS v2 completed the prediction-generation phase, identifying over 478,000 synergy predictions and 6,000 multi-cell-line combinations.
  • Algorae partnered with AgenticScale.ai in the Sovereign AI Infrastructure initiative.
  • Financial position showed $3.94 million cash at 30 June 2026, with total available funding of $6.94 million.
  • Subsequent to the quarter, Algorae secured an NSW Health public hospital supply contract.
  • Received positive validation results from a program at Peter Mac and a $49,109 grant from Phenomics Australia.
  • Appointed Mr. Troy Valentine to the Board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.